New hope for COPD sufferers? experimental drug Hemay005 enters Mid-Stage trial

NCT ID NCT07314242

First seen Jan 05, 2026 · Last updated May 11, 2026 · Updated 17 times

Summary

This study tests an experimental drug called Hemay005 in 120 adults with moderate to severe COPD, a long-term lung disease that makes breathing difficult. The goal is to see if the drug can reduce lung inflammation and improve symptoms compared to a placebo or an existing medication. Participants will receive either Hemay005, a dummy pill, or an active comparator, and researchers will monitor their lung function and safety over several weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • China People's Armed Police Force Characteristic Medical Center

    Tianjin, 300162, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Fourth Central Hospital

    Tianjin, 300074, China

    Contact

Conditions

Explore the condition pages connected to this study.